脳深部刺激（DBS）とは、脳の運動を司る部分に信号を伝達する装置を埋め込む手術です。DBSは、ジストニア、パーキンソン病、本態性振戦などの神経疾患によるこわばり、だるさ、歩行困難などの症状を緩和します。少なくとも5年間、薬に反応しなかった患者は、この治療法を検討することができます。さらに、FDAは、てんかん発作の原因となる脳の領域を分離または除去するてんかん手術を受けることができない人に対しても、この薬を承認しています。その結果、アルツハイマー病やパーキンソン病などの神経系疾患の頻度が高まり、市場拡大の主な要因となっています。
Globe Ageing 2019の調査によると、2019年の世界の65歳以上の人口は約7億300万人でした。2050年には、この人口は15億人に増加すると予想されています。さらに、2050年までに、地球上の6人に1人が65歳を超え、2019年の11人に1人から増加すると予想されます。高齢者の人口は増加すると予想されており、このグループは神経系の問題を抱えやすいため、近い将来、市場を牽引することになるでしょう。
目次
Contents
1. Executive Summary
2. Global Deep Brain Stimulation Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Deep Brain Stimulation Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Deep Brain Stimulation Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Deep Brain Stimulation Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia, Thailand, Malaysia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Latin America: (Brazil, Mexico, Argentina, Colombia, Chile and Venezuela), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. MEA: (South Africa, Saudi Arabia, UAE, Turkey and Iran), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Stimulation Type: Market Share (2020-2030F)
12.2.1. Subthalamic DBS, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Globus Pallidus DBS, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Thalamic DBS, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Pedunculopontine Nucleus DBS, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Product: Market Share (2020-2030F)
12.3.1. Single Channel Deep Brain Stimulator, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Dual Channel Deep Brain Stimulator, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Application: Market Share (2020-2030F)
12.4.1. Parkinson's Disease (PD), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Epilepsy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Dystonia, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Obsessive Compulsive Disorder (OCD), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5. By End-User: Market Share (2020-2030F)
12.5.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Ambulatory Surgical Centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.3. Neurological Centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. Company Profile
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Medtronic
13.3. Boston Scientific Corporation
13.4. Aleva Neurotherapeutics S.A.
13.5. Nexstim
13.6. LivaNova PLC
13.7. Neuropace Inc.
13.8. Renishaw PLC
13.9. Beijing PINS Medical Co. Ltd
13.10. Fisher Wallace
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
